Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
USHY vs XBI: how they differ
USHY and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
iShares Broad USD High Yield Corporate Bond ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, USHY and XBI hold 0% of their money in the same securities at the same weight.
| Only in USHY | Only in XBI |
|---|---|
| BLK CSH FND TREASURY SL AGENCY 1.17% | MODERNA INC 2.87% |
| 1261229 BC LTD 144A 0.49% | TWIST BIOSCIENCE CORP 1.81% |
| MERIDIAN ARC HOLDCO LLC 144A 0.38% | HALOZYME THERAPEUTICS INC 1.47% |
| PR RNO PROPERTY OWNER 1 LLC 144A 0.29% | NATERA INC 1.46% |
| GALAXY HELIOS DATA CENTERS II LLC 144A 0.24% | KYMERA THERAPEUTICS INC 1.45% |
| SV RNO PROPERTY OWNER 1 LLC 144A 0.24% | TRAVERE THERAPEUTICS INC 1.40% |
| WULF COMPUTE LLC 144A 0.24% | ROIVANT SCIENCES LTD 1.39% |
| CORE SCIENTIFIC FINANCE I LLC 144A 0.23% | ORUKA THERAPEUTICS INC 1.38% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 10, 2026.
| USHY iShares Broad USD High Yield Corporate Bond ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | Broad USD High Yield Corporate Bond | SPDR S&P Biotech |
| Total return, 1 year | +3.3% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −14.2 pts | +46.5 pts |
| Expense ratio | 0.08% | 0.35% |
| Holdings | 1871 | 154 |
USHY in plain words
USHY is a bond fund tracking the Broad USD High Yield Corporate Bond. Over the year to Sep 11, 2026 it returned +3.3% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.08% a year.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, USHY or XBI?
- In the year to Sep 13, 2026, with distributions reinvested, USHY returned +3.3% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, USHY or XBI?
- USHY charges 0.08% a year and XBI charges 0.35%, so USHY is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, USHY against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/ushy-vs-xbi Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources